Free Trial
NYSE:JNJ

Johnson & Johnson Q2 2025 Earnings Report

Johnson & Johnson logo
$156.87 -0.82 (-0.52%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$156.75 -0.12 (-0.08%)
As of 07/11/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson EPS Results

Actual EPS
N/A
Consensus EPS
$2.65
Beat/Miss
N/A
One Year Ago EPS
N/A

Johnson & Johnson Revenue Results

Actual Revenue
N/A
Expected Revenue
$22.85 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Johnson & Johnson Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 16, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Johnson & Johnson Earnings Headlines

Johnson & Johnson (NYSE:JNJ) Price Target Raised to $171.00
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Johnson & Johnson Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Johnson & Johnson? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Johnson & Johnson and other key companies, straight to your email.

About Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) (NYSE: JNJ) is a diversified global healthcare company founded in 1886 and headquartered in New Brunswick, New Jersey. Over its more than 135-year history, the company has evolved from a single–product focus on sterile surgical supplies into a broad-based provider of pharmaceuticals, medical devices and consumer health products. Johnson & Johnson’s long-standing commitment to research and innovation has driven the development of numerous groundbreaking treatments and technologies, solidifying its reputation as a leader in healthcare.

The company operates through three primary business segments. Its Pharmaceutical segment focuses on therapeutic areas such as immunology, oncology, neuroscience, cardiovascular and metabolic diseases, and infectious diseases. In the Medical Devices segment, Johnson & Johnson designs and manufactures products for orthopedics, surgery, interventional solutions and vision care. The Consumer Health segment develops and markets well-known over-the-counter products in categories that include baby care, oral care, wound care, women’s health and skincare.

Johnson & Johnson maintains a global presence, with operations spanning more than 60 countries and products sold in virtually every national market. The company invests heavily in research and development, operating multiple innovation centers and collaboration hubs around the world to advance new medical discoveries. Its extensive supply chain network and manufacturing facilities ensure timely delivery of products to hospitals, pharmacies and retail outlets.

Leadership at Johnson & Johnson emphasizes both operational excellence and social responsibility. Joaquin Duato was appointed Chairman and Chief Executive Officer in January 2022, bringing more than three decades of experience in roles spanning R&D, commercial operations and global strategy. Under his guidance, the company continues to pursue sustainable growth, strengthen its pipeline of new therapies and devices, and uphold commitments to ethical standards and community health initiatives worldwide.

View Johnson & Johnson Profile

More Earnings Resources from MarketBeat